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Abstract 
Increased prevalence of inflammatory airway diseases including asthma and chronic 
obstructive pulmonary disease (COPD) together with a significant number of patients 
being inadequately controlled by current frontline treatments means that there is a 
need to define novel therapeutic targets for these conditions1. Here we investigate a 
member of the G protein-coupled receptor (GPCR) family, FFA4, which responds to 
free circulating fatty acids, including dietary omega-3 fatty acids found in fish oils2-4. 
Although usually associated with metabolic responses linked with food intake, we 
show that FFA4 is expressed in the lung where it is coupled to Gq/11-signalling. 
Activation of FFA4 by drug-like agonists produced relaxation of murine airway smooth 
muscle mediated, at least in part, by the release of the prostaglandin PGE2 that 
subsequently acts on EP2 prostanoid receptors. In normal mice, activation of FFA4 
resulted in a decrease in lung resistance. Importantly, in acute and chronic ozone 
models of pollution-mediated inflammation, and in house-dust mite and cigarette 
smoke-induced inflammatory disease, FFA4 agonists acted to reduce airway 
resistance, whilst this response was absent in mice lacking expression of FFA4. The 
expression profile of FFA4 in human lung was very similar to that observed in mice 
and the response to FFA4/FFA1 agonists similarly mediated human airway smooth 
muscle relaxation. Hence, our study provides evidence that pharmacological targeting 
of lung FFA4, and possibly combined activation of FFA4 and FFA1, has in vivo efficacy 
that might have therapeutic value in the treatment of bronchoconstriction associated 
with inflammatory airway diseases such as asthma and COPD.  
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Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory 
inflammatory diseases that affect >500 million people worldwide, causing substantial 
morbidity and exacting a considerable cost to health services5-7. Despite the 
effectiveness of current therapies the heterogeneity of these conditions means that 
~45% of asthmatics remain uncontrolled and in COPD the combination of 
corticosteroid, long-acting muscarinic antagonists and b-adrenoceptor agonists 
inadequately control symptoms and exacerbations in many patients5-8. We have 
addressed the urgent need to understand novel paradigms in lung physiology that 
might reveal new therapeutic strategies by focusing on the role and potential clinical 
value of a member of the G protein-coupled receptor (GPCR) super-family, FFA4 
(previously known as GPR120). This GPCR responds to a range of free circulating 
long chain (>C12) fatty acids (LCFAs) that include the diet-derived essential fatty acids 
linoleic and a-linolenic acid as well as omega-3 polyunsaturated fatty acids prevalent 
in fish oils2-4. The majority of previous studies on FFA4 have focused on the regulation 
of physiological responses associated with food intake. Expressed on entero-
endocrine cells of the gut9,10, various cell types in pancreatic islets11,12, white adipose 
tissue13, and on immune cells, particularly macrophages14, FFA4 has been strongly 
implicated in the regulation of glucose homeostasis12 and inflammation, particularly in 
connection with adipose tissue in animals fed on a high fat diet15. These data, together 
with the emergence of a number of small “drug-like” ligands to FFA43, has fuelled 
interest from both academia and industry in targeting FFA4 for the treatment of 
metabolic disease including type II diabetes and obesity4.  
It has however recently become clear that FFA4 is abundantly expressed in lung 
epithelial cells16 and a recent study suggested that omega-3 fatty acids acting via 
FFA4 receptors might have some beneficial effects on airway epithelial repair following 
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naphthalene-induced airway injury17. Other than this study, the role that FFA4 might 
play in lung physiology is completely unknown. Here, we use a combination of novel 
pharmacological agents, genetically engineered mice and both ex vivo and in vivo 
techniques, to determine that FFA4 receptors expressed in mouse and human 
airways, mediate airway smooth muscle relaxation in a manner that is relevant in both 
normal physiology and inflammatory airway disease. 
 
Expression of FFA4 in mouse airways 
Using both RT-PCR (fig 1a) and qRT-PCR (fig 1b) we confirmed the presence of 
FFA4 mRNA in the mouse lung at levels substantially higher than seen for a second 
receptor for LCFAs, FFA1 (figs 1a,b) and confirmed the lack of expression of FFA4 
mRNA in equivalent samples from a genetically engineered mouse strain where the 
first exon of the FFA4 gene was replaced with the coding sequence of b-galactosidase 
(FFA4-KO(bgal) mice) (figs 1a,b). To investigate the tissue distribution of FFA4 
further, we stained for b-galactosidase in FFA4-KO(bgal) mice as this acts as a 
surrogate marker for FFA4 expressing cells. Using this approach we established that 
FFA4 is expressed primarily in cells of the airway epithelium (fig 1c). These data are 
supported by studies using an in-house generated mouse FFA4 selective antiserum18 
where it was confirmed that FFA4 expression was primarily associated with the 
epithelium of the mid- and lower-airways, with very much lower levels of expression 
associated with airway smooth muscle (ASM), as defined by the presence of a-actin 
(fig 1d). Co-staining with an antiserum to club cell specific protein 10 (CC10) 
demonstrated that at least one cell type expressing FFA4 in the airway epithelium was 
club cells (fig 1e), a result consistent with a recent mRNA analysis that identified high 
level enrichment of FFA4 transcript levels in club cells19. 
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FFA4 mediates airway smooth muscle relaxation and bronchodilation  
To probe the activity of FFA4 we used a well characterized agonist, TUG-89120-24, 
which has activity at both FFA1 and FFA4 (fig 2a). In addition we employed the 
recently generated agonist TUG-119725 that we confirm here selectively activates 
FFA4 but not FFA1 (fig 2b). Importantly, FFA4 has previously been shown to signal 
in a bimodal fashion, initiating signal transduction via heterotrimeric G proteins as well 
as through a mechanism operating via the recruitment of arrestin adaptor proteins18,20-
22. Our previous studies have established that the recruitment of arrestin3 in response 
to TUG-891 is nearly totally dependent on receptor phosphorylation and mediates 
processes such as receptor internalization18,21. Here we show that TUG-1197 acts as 
an agonist at FFA4 in both G protein-dependent signalling, as measured by Gq/11-
mediated calcium mobilization (fig 2b) and activation of Extracellular Regulated 
Protein Kinase 1/2, (ERK1/2; fig 2c,d). In addition, TUG-1197 also is an agonist at 
promoting arrestin3 recruitment (fig 2e), receptor phosphorylation (fig 2f) and receptor 
internalization (fig 2g). Hence, the signalling properties of TUG-1197 indicated that 
this ligand is a selective agonist at FFA4, initiating signalling through canonical G-
protein and arrestin pathways. TUG-1197 is therefore a useful tool ligand for probing 
the physiological activity of FFA4. Moreover, whilst also able to activate FFA1 (fig 2a) 
TUG-891 was able to mimic all the effects of TUG-1197 at FFA4 (fig 2c-g). 
In precision cut lung slices (PCLS) derived from wild type mice, TUG-1197 induced a 
rapid increase in intracellular calcium (fig 2h). In contrast, no significant calcium 
response to TUG-1197 was observed in PCLS derived from FFA4-KO(bgal) mice (fig 
2i). Furthermore, the calcium response to TUG-1197 in PCLS from wild type mice was 
significantly inhibited by the Gq/11-blocker, FR90035926 (fig 2j). From these data it was 
concluded that FFA4 in the lung is functionally active and couples to the 
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Gq/11/phospholipase C/inositol phosphate signal transduction cascade and that the 
activity of our tool compounds TUG-891 and TUG-1197 in driving a calcium response 
in lung tissue is exclusively via FFA4. 
Since FFA4 mediated a strong calcium response in PCLS the possibility that FFA4 
might promote ASM contraction was examined. Application of the bronchoconstrictors, 
carbachol or serotonin, resulted in narrowing of airways in PCLS (fig S1a-c), 
responses that act here as a positive control. In contrast, the application of TUG-891 
or TUG-1197, at concentrations that resulted in robust calcium responses in PCLS 
(e.g. 50µM (fig 2h)) did not result in any significant change in the diameter of airways 
in PCLS (fig S1b, c). These data indicated that FFA4 did not mediate ASM 
contraction. Instead, experiments designed to test the possibility that FFA4 agonists 
could promote ASM relaxation revealed that both TUG-891 and TUG-1197 acted in a 
concentration-dependent manner to increase the diameter of airways pre-contracted 
with carbachol (fig 3a-d) with pEC50 values of 4.60 ± 0.10 and 4.77 ± 0.15 respectively.  
In the case of FFA4-mediated ASM relaxation the maximal effective concentration of 
either TUG-891 or TUG-1197 returned airways to 70-80% of the diameter observed 
before carbachol pre-treatment (fig 3a-d). Importantly, the response to both TUG-891 
and TUG-1197 was significantly reduced by the FFA4 selective antagonist AH761427 
(fig 3e,f and fig S2a,b). Similarly, ASM relaxation to TUG-1197 was significantly 
diminished in PCLS derived from FFA4-KO(bgal) mice (fig 3g,h). In both the 
antagonist experiments and in FFA4-KO(bgal) mice, there was a small response to 
TUG-1197 and TUG-891 which may represent some off-target effect of these ligands. 
However, further support for a broncho-relaxation response of FFA4 activation was 
evident from our studies using a chemically distinct, and previously described, 
selective FFA4 agonist, Merck Compound A15. This agent showed similar FFA4 
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agonist properties (pEC50 and Emax) to TUG-1197 and TUG-891 in in vitro calcium 
mobilization assays (pEC50 values of 6.76, 6.77, 6.00 for TUG-891, TUG-1197 and 
Compound A, respectively) (fig S3a). Importantly, in PCLS, Compound A mimicked 
the effects of TUG-891 and TUG-1197 in reducing ASM contraction (fig S3a-c). 
Finally, the relaxation response to FFA4 agonists was not restricted to airways pre-
treated with carbachol since airways pre-contracted with serotonin (5HT) were also 
seen to be similarly relaxed in response to TUG-1197 (fig S4a,b).  
 
FFA4 mediates bronchodilation in normal lung physiology and disease 
The data from the above ex vivo experiments led to the prediction that FFA4 agonists 
would increase the diameter of airways and thereby decrease airway resistance in 
vivo. This was tested in anaesthetised mice where airway resistance was elevated via 
administration of nebulized acetylcholine28. Under these conditions, the response to 
acetylcholine alone in FFA4-KO(bgal) was comparable to that observed in wild-type 
mice (fig 4a (compare vehicle treated mice). The effect of activation of FFA4 on the 
acetylcholine response was tested by co-administration of nebulized TUG-891 or 
TUG-1197 with acetylcholine. Under these conditions the acetylcholine-mediated 
increase in resistance was significantly attenuated (fig 4a, and fig S5). Importantly, 
there was no significant response to TUG-1197 in FFA4-KO(bgal) mice (fig 4a). 
We next tested the effects of FFA4 activation within the context of an acute 
model of ozone pollution-induced inflammation. Under these conditions we observed 
no significant hyper-responsiveness induced by exposure to ozone but nevertheless 
administration of TUG-1197 was again seen to decrease airway resistance in wild type 
mice. This response to TUG-1197 was once more absent in FFA4-KO(bgal)  mice (fig 
4b). This was extended by testing the effects of FFA4 activation in a model of chronic 
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(3 week) ozone exposure, which produced a profound inflammatory response as 
indicated by an increase in immune cells in broncho-alveolar lavage (BAL) fluid that 
included, alveolar macrophages, monocyte-derived macrophages and neutrophils, as 
well as up-regulation of the inflammatory mediators KC/CXCL1 and TNFa (fig 4c-h). 
This inflammatory response was accompanied by significant airway hyper-
responsiveness (fig 4i,j). Under these conditions, administration of TUG-891, given 1 
hr prior to each ozone exposure over the 3 week period, significantly decreased airway 
hyper-responsiveness (fig 4i) as well as decreasing airway inflammation as indicated 
by reduction of immune cells in the BAL fluid (fig 4c-f) and reduced levels of 
inflammatory markers (fig 4 g-h).  
The effects of TUG-891 on neutrophil infiltration in the chronic ozone model 
prompted us to test the possibility that FFA4-induced anti-inflammatory effects might, 
at least in part, be mediated via modulation of leukotriene-mediated neutrophil 
infiltration. To assess this we analysed the transcript levels of 5-LOX, the enzyme 
responsible for LTB4 production, and the transcript levels of the BLT1 and BLT2 (BLT1 
is the high affinity, and BLT2 the low affinity, LTB4 receptor). We found that mRNA 
encoding these genes was unchanged by 3 week ozone exposure and that TUG-891 
treatment similarly had no effect on transcript levels (fig S6a-c), although there was a 
small trend towards a decrease of BLT1. Interestingly, the levels of LTB4 itself were 
seen to increase with chronic ozone treatment and this increase was prevented 
by administration of TUG-891 (fig S6d). That other factors may contribute to airway 
neutrophil infiltration, including increased production of the T helper 17 cell (TH17) 
interleukin IL17a29-32 was also considered, however, mRNA corresponding to this 
ligand was unchanged following chronic ozone exposure or treatment with TUG-891 
(fig S6e).  
 10 
Interestingly, FFA4 expression was detected in BAL cells that were also 
positively stained for each of CD11c, GR-1 and SiglecF (fig S7). These are markers 
respectively of monocytes, macrophages and dendritic cells, indicating that FFA4 
activation might have a direct anti-inflammatory effect via these immune cells. It is also 
noteworthy that FFA4 was not detected in CD3+ or B220+ cells which are markers of 
T-lymphocytes which suggests that FFA4 is not expressed by T-lymphocytes (fig S7).  
Whilst the above described data indicate that FFA4 has an anti-inflammatory 
role that could contribute indirectly to reduced hyper-responsiveness, results shown 
in fig 3 on PCLS and in live mice in fig 4a,b, point to a more direct role for FFA4 on 
ASM relaxation. We therefore tested if acute FFA4 activation could reduce airway 
resistance in mice in which hyper-responsiveness had already been induced by 
chronic exposure to ozone. This potential was supported by data demonstrating that 
FFA4 transcript levels were not affected by chronic ozone exposure (fig S8a) nor was 
FFA4 signalling (calcium mobilization) altered (fig S8b,c). In settings in which hyper-
responsiveness had been induced in mice by chronic ozone exposure, administration 
of TUG-891 together with acetylcholine significantly reduced airway resistance (fig 4j), 
indicating that FFA4 agonism can produce ASM relaxation, even in the context of an 
already established inflammatory lung disease.  
In an alternative disease model we induced airway hyper-responsiveness by 
an 8-wk exposure to cigarette smoke (fig 5a). This procedure correlated with 
significant inflammation as indicated by an increase in numbers of aveolar 
macrophages and neutrophils (fig 5b,c). Acute administration of TUG-891 by 
nebulization prior to treatment with a bronchoconstrictor resulted in a reversal of hyper-
responsiveness (fig 5a) indicating that, similar to the chronic ozone model, FFA4 
activation in this cigarette smoke model was able to produce ASM relaxation.  
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Importantly, FFA4 activation in the smoke model also appeared to be anti-
inflammatory because chronic administration of TUG-891 prior to exposure to each 
cigarette also prevented airway inflammation as measured by a reduction in alveolar 
macrophages and neutrophils at termination of the study (fig 5b,c).  
Finally, we induced airway hyper-responsiveness in mice by sensitization to 
house dust mites (HDM). Following sensitisation, immune cell count in the BAL fluid 
(fig 5d), and specifically CD4+ T cells (fig 5e) and eosinophils (fig 5f), was seen to 
increase, consistent with the notion that this model reproduces important features of 
allergic asthma33. Daily administration of TUG-891, after the initial sensitization and 
before the final HDM challenge, significantly reduced airway hyper-responsiveness 
(fig 5g). Alongside the ozone and cigarette-smoke models these data indicate that 
FFA4 activation can ameliorate airway inflammation and hyper-responsiveness in the 
context of multiple respiratory disease models. 
 
FFA4 is expressed in human airways and mediates bronchodilation  
Transcript levels of FFA4 in human bronchial epithelial cells (HBEC) and human 
airway smooth muscle (ASM) derived from healthy donors was detected by PCR and 
qPCR (fig 6a,b). We confirmed the selectivity of a previously characterized, in-house 
human (h) selective FFA4 antiserum21 raised against a C-terminal peptide of hFFA4 
(K342-R353) in Western blots of lysates prepared from Chinese hamster ovary (CHO) 
cells transfected with hFFA4. In these experiments hFFA4 was detected as a broad 
band running at ~50kDa only in lysates from hFFA4 transfected cells (fig 6c). This 
same antiserum detected hFFA4 in membrane and intracellular locations in 
immunofluorescent studies of hFFA4 transfected CHO cells (fig 6d). Using this 
antiserum we investigated the expression profile of hFFA4 in isolated HBEC and ASM 
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by flow cytometry (fig 6 e,f) and immunocytochemistry (fig 6 g,h) as well as in 
immunohistochemistry performed on human bronchial biopsies (fig 6i-l and fig 
S9a,b). These experiments established that hFFA4 was primarily expressed in the 
human airway epithelium with lower levels in the ASM.   
The expression profile observed in human lung closely mirrored that seen in the 
mouse lung (see; fig 1c,d), further suggesting that the mouse airway responses 
reported here might mimic those of hFFA4 in human airways. This possibility was 
tested further by monitoring calcium mobilization in response to TUG-891 in human 
ASM and HBECs. TUG-891 (50 μM) caused a statistically significant increase in 
calcium mobilization in both ASM and HBEC cells (fig 7 a,b). We next assessed if 
FFA4 in human ASM might mediate relaxation using a collagen gel preparation where 
human ASM contraction can be monitored by reduction in the diameter of the collagen 
gel34. Treatment of ASM in this preparation with TUG-891 reversed both spontaneous 
contraction and contraction observed in the presence of the bronchoconstrictor, 
acetylcholine (fig 7 c,d). These data demonstrate that FFA4 is expressed and 
functional in isolated human ASM cells and that activation of this receptor is able to 
promote human ASM relaxation ex vivo.  
We extended these studies by testing human ASM contractile responses in 
intact lung tissue (un-denuded bronchi) isolated from healthy subjects using wire 
myography. In these experiments TUG-891 produced a concentration-dependent 
(pEC50, 4.34 ± 0.13) relaxation of human airways that had been pre-contracted with 
acetylcholine (fig 7e). 
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Potential role of prostaglandins in the mechanism of FFA4-mediated 
bronchodilation 
It has been known for some time that through an interplay between EP1 (contraction) 
and EP2 (relaxation) prostanoid receptors, prostaglandins can regulate lung function, 
via both contraction and relaxation of ASM35. Among the prostanoids reported to have 
an impact on lung function is prostaglandin PGE2 35. Released from various lung cell 
types including ASM 36-38, airway epithelium 39 and immune/inflammatory cells of the 
lung 40, PGE2 can mediate bronchodilation via EP2 receptors41-43. Interestingly, the 
bronchodilation properties of a number of GPCR ligands including bradykinin, 
substance P, ATP, and proteases that activate the proteinase activated receptors (i.e. 
PAR2), are mediated by the release of PGE2 37,44,45. Therefore, in addition to directly 
acting on ASM we tested the possibility that FFA4 might also mediate bronchodilation 
via the release of PGE2. Incubation of PCLS derived from wild type mice with TUG-
891 resulted in a significant release of PGE2 whereas the same concentration of TUG-
891 applied to PCLS from FFA4-KO(bgal) mice generated no significant PGE2 release 
(fig 8a). Importantly, we confirmed that PGE2 administration to pre-contracted PCLS 
derived from wild type mice resulted in relaxation of ASM (fig 8b). Moreover, the EP2 
selective antagonist, PF-04418948 46, significantly blocked the relaxation of ASM in 
response to TUG-891 in PCLS (fig 8c). TUG-891 was used in this set of experiments 
since our in vitro studies indicated that it is the more potent of the two compounds (fig 
2a,c,e). Finally we measured PGE2 levels in the BALF from mice exposed to 
ozone and treated with TUG891. In these experiments we observed a significant 
increase in PGE2 following chronic administration of TUG891 (fig 8d). 
Previous work has highlighted species differences in the roles of prostanoid 
receptor subtypes in mediating PGE2-dependent airway relaxation, with EP2 being the 
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predominant subtype in the mouse and EP4 the key subtype in human47,48. We 
confirmed here expression of all four known EP prostanoid receptors (EP1-4) in isolated 
human bronchial epithelial cells (fig S10a). However, only EP2-4 were expressed in 
human ASM (fig S10b).  
To further investigate the mechanism by which FFA4 mediates increased PGE2 
production in mouse, gene expression analysis was performed in lung tissues 
obtained from the 3-wk ozone exposure model. In this experiment, mRNA levels of the 
majority of genes involved in the biosynthesis of PGE2, including PGE2 synthases and 
cyclooxygenase-1 (COX1) were not significantly altered whilst there was a small, but 
significant, up-regulation of cyclooxygenase-2 (COX2) mRNA (fig S11 a-e). This 
suggests that FFA4 activation may induce expression of COX2 to increase PGE2 
levels.  However, further work would be required to assess the significance of this 
observation not least because other mechanisms might be in play to regulate PGE2 
levels such as availability of arachidonate and post-translational regulation of synthetic 
enzyme activity. Importantly, in the 3-wk ozone exposure model expression of the EP2 
receptor was not significantly altered (fig S11 f), highlighting that this pathway would 
still be expected to be operational in the disease state.  
Because the FFA4 agonists appeared to produce a response via EP2 receptors 
we assessed if either TUG-891 or TUG-1197, which represent very different 
chemotypes, could directly activate EP2 receptors. In these experiments TUG-891 (10 
µM) produced no significant activation of the EP2 receptor (table S1). TUG-891 also 
lacked agonist function at other EP prostanoid receptors, including the EP1 receptor 
(table S1). Equally TUG-891 did not significantly block effects of endogenously 
generated prostanoids at any of the EP prostanoid receptors (table S2). A similar lack 
of effect of 10 µM TUG-1197 as an agonist (table S1) or antagonist (table S2) on each 
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of the EP1-4 prostanoid receptors was recorded. These data provide further support 
that the effect of ligands with potency at FFA4, in both ex vivo and in vivo studies, is 
indeed mediated by FFA4 (and not via off-target activity at, for example, prostanoid 
receptors).  
Since we established a link here between FFA4 bronchodilation and PGE2 
we wanted to test if PGE2 might also be involved in the FFA4-mediated anti-
inflammatory response observed in mouse disease models. That this might be 
the case was indicated by the observation that PGE2 levels were increased in 
BALF following chronic administration of a FFA4 agonist in the ozone model (fig 
8d) - a response that correlated with an increase in COX2 transcription (fig S11 
a-e), the enzyme response for prostaglandin biosynthesis including PGE2. In an 
attempt to investigate this possibility we tested the effects of the COX2 inhibitor 
celecoxib on the FFA4-mediated anti-inflammatory response by monitoring 
changes in number of cells ,TNFa levels and IL-1b  transcript in BALF from mice 
chronically exposed to ozone. In these experiments celecoxib alone was anti-
inflammatory which phenocopied TUG-891 anti-inflammatory response (fig S12 
a-c). The co-administration of celecoxib and TUG-891 provided an anti-
inflammation effect equivalent to celecoxib and TUG-891 alone (fig S12 a-c). 
Hence, unlike the bronchodilation response where it was possible to define a 
role for PGE2 in the FFA4 response we were not able to conclude from these 
experiments a specific role for PGE2 in FFA4-mediated anti-inflammation. 
  
Discussion 
We present evidence that the GPCR, FFA4, is expressed and active in the murine 
lung, where activation of the receptor mediates ASM relaxation under both normal 
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physiological conditions and in the context of respiratory disease models whilst, 
additionally, generating an anti-inflammatory effect. That these mouse studies have 
applicability to human disease is supported by data establishing FFA4 expression and 
function in human ASM and bronchial epithelial cells (HBEC) and in producing 
relaxation of human ASM in response to the agonist TUG-891. Together, our data 
support the conclusion that the long chain free fatty acid receptor FFA4 might be a 
tractable pharmacological target for the treatment of human airway diseases. 
 It is important to note the FFA4 selective agonist TUG-1197, and the FFA1/FFA4 co-
agonist TUG-891, were equally effective in mouse lung ex vivo and in vivo 
experiments. However, in human cell and tissue-based studies we found that TUG-
891 was more effective. Although this might be explained by the fact that TUG-891 is 
slightly more potent than TUG-1197 at FFA4 it might also suggest that, in addition to 
FFA4, FFA1 may also contribute to the airway responses reported here, particularly 
in human lung where the expression of functional FFA1 has been reported 49. In 
contrast to our data however an ex vivo study has suggested that FFA1 might augment 
acetylcholine mediated ASM contraction rather than mediate ASM relaxation 49. Since 
our data supports the opposite possibility we would argue that there is a potential for 
dual FFA1/FFA4 agonists to be more effective agents at mediating ASM relaxation 
than FFA4 selective agonists. Hence, testing dual agonists alongside FFA4 selective 
agents in experimental medicine studies will determine which approach is desirable 
ahead of human clinical trials. It will also be important to reduce the possibility of off-
target adverse responses before human trials by significantly increasing the potency 
of our current tool compounds. That off-target activity of our current ligands may exist 
is indicated by the small calcium transient (see; fig 2i) and trend (although not 
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significant) relaxation response to TUG-1197 in PCLS derived from FFA4-KO(bgal) 
mice (see; fig 3h). 
We provide evidence that one mechanism of action of FFA4 in promoting ASM 
relaxation in mouse is via receptor-mediated release of the prostaglandin PGE2 that 
subsequently acts at the EP2 prostanoid receptor to mediate relaxation. A similar 
mechanism of ASM relaxation has been reported for other GPCRs 37,44,45 raising the 
question of whether an alternative approach in a therapeutic context might be to 
directly target EP2 to deliver ASM relaxation. However, prostanoid biology in the lung 
is complex. For example, EP4 is considered as the most predominant subtype in 
human47,50 and therefore targeting specifically EP2 would be less likely to be effective 
in human. Moreover, PGE2 has multiple modes of action in that it can activate four 
different receptor subtypes (EP1-EP4) which transduce a variety of processes including 
bronchodilation, cough, microvasculature leaks and regulation of pulmonary blood 
vessel tone48,51,52. Our data also show that mRNA encoding each of the four subtypes 
can be detected in human ASM and/or bronchial epithelial cells. As such, the indirect 
generation and action of PGE2 produced via activation of FFA4 may contribute to the 
highly beneficial outcomes observed via a number of receptors, whilst a selective 
agonist for one or other subtype might fail to produce the integration of outcomes 
generated by the native prostanoid.  
Our study points to FFA4 having a dual effect in the context of inflammatory airway 
disease. The first centres on an action on the ASM resulting in bronchodilation with 
the potential of symptomatic relief in conditions such as asthma where airway 
constriction is a feature. Although our studies on human airways (collagen gel 
contraction) point to a direct effect of FFA4 on ASM the relatively high levels of 
expression of this receptor on epithelial cells means that an indirect effect cannot be 
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ruled out. It is possible for example that the airway epithelium is the origin of FFA4-
mediated PGE2 release that subsequently leads to ASM relaxation. Secondly, our data 
point to a role for FFA4 in the regulation of inflammation that is consistent with reports 
that FFA4, expressed on various immune cells including macrophages 14,53, can act 
as a negative modulator of inflammation  in the context of metabolic disease 14,15,54. 
Exposure of mice to repeated doses of ozone resulted in a profound inflammatory 
response, evidenced by an increase in immune cells (neutrophils and macrophages) 
in the airway spaces and a corresponding elevation of gene expression for the 
macrophage pro-inflammatory cytokine TNFα, and the neutrophil chemotactic factor, 
KC/CXCL1. Importantly, intranasal pre-treatment of mice with TUG-891 prior to each 
exposure to ozone significantly reduced the expression of these pro-inflammatory 
cytokines and prevented immune cell infiltration. Thus, our data indicates that in 
addition to an effect on ASM contraction that has the potential for symptomatic 
treatment of inflammatory airway disease, FFA4 activation could also have an anti-
inflammatory property that would provide for disease modification.  
It is not clear from our study whether the dual action of FFA4, namely relaxation of 
ASM and anti-inflammation, is via a shared mechanism. For example, we provide 
evidence that ASM relaxation is in part mediated by the release of PGE2 acting on EP2 
receptors however we currently have no evidence for the involvement PGE2 release 
in the anti-inflammatory response. The detection of FFA4 expression in CD11c, GR-1 
and SiglecF positive immune cells in the lung might indicate that FFA4 has a direct 
role in regulating immune cell response and therefore a distinct anti-inflammatory 
mechanism from that which mediates ASM relaxation. Despite these unresolved 
questions regarding the mechanism and cell types involved in mediating FFA4 dual 
 19 
effects on ASM and inflammation our study reveals the therapeutic potential of 
targeting FFA4 in inflammatory lung disease. 
A further important question that remains to be addressed is the origin of endogenous 
LCFAs that regulate lung FFA4. It is noteworthy that we observed no significant 
difference in the ‘basal’ airway resistance between wild type and FFA4-KO mice (see; 
fig 4a) indicating that more sensitive approaches and possibly additional mouse 
models that modulate endogenous lung fatty acid metabolism will be required to fully 
appreciate the role of endogenous free fatty acids. However, the omega-3 fatty acids, 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been reported 
to be enriched in airway mucosa55 where they are proposed to act as precursors for 
the biogenesis of lipid mediators such as the resolvins that resolve inflammatory 
responses56, including lung inflammation30 via interacting with members of the GPCR 
family including the chemerin-1 and chemerin-2 receptors. Whether this enriched pool 
of dietary-derived omega-3 fatty acids, that can potentially be augmented by the 
recruitment of circulating DHA and EPA at the sites of inflammation57 or that can be 
released from membranes by the activity of phospholipase A258, might be the source 
of endogenous LCFA activators for FFA4 is a possibility that is currently under 
investigation.  
Importantly, our data demonstrated that expression of FFA4 in human airways is 
similar to that observed in mouse and that FFA4 agonism promotes relaxation isolated 
human ASM and of human airway strips. In this way we provide unique proof-of-
concept that pharmacological activation of lung FFA4 can generate in vivo efficacy. 
The precise pharmacological properties of a clinically effective hFFA4 agonist, 
particularly whether a full/partial agonist or whether a dual FFA4/FFA1 agonist would 
be most efficacious or indeed whether a G protein-biased ligand that might avoid 
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potential challenges such as receptor desensitization and tachyphalaxis20, is 
preferable has yet to be fully established. Our study does however provide the first 
evidence that FFA4 can indeed promote airway relaxation and resolve airway 
inflammation, and thus may be a “druggable” target for the treatment of airway 
diseases associated with bronchoconstriction and inflammation. 
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Fig 1 
FFA4 receptors are expressed in murine lung and localise primarily to the 
epithelial layer. (a) Transcript levels of FFA1, FFA4 and tubulin (as a control) were 
identified in lung from wild type and FFA4-KO(βgal) mice using RT-PCR. Shown is a 
representative gel of 3 independent experiments. The expected sizes of PCR products 
are as follows; FFA4 = 800 base pairs (bp), tubulin = 750 bp and FFA1 = 530 bp.  (b) 
Quantitative RT-PCR of the lung tissue samples from wild type and FFA4-KO(βgal) 
mice was conducted using GAPDH housekeeping gene as a control. Data represent 
mean ± S.D. of 4-10 independent experiments. (c) Representative confocal image of 
lung tissue sections obtained from FFA4-KO(βgal) mice and stained for β-
galactosidase as a surrogate for FFA4 expression. (d) Representative images of lung 
tissue sections obtained from wild-type (left) and FFA4-KO(βgal) (right) mice co-
stained with an in-house generated mouse FFA4 specific antiserum (green), α-actin 
antibody to stain ASM (red) and DAPI to identify nuclei (blue). (e) Immunofluorescence 
co-staining of mouse FFA4 and club cell marker (CC10). The images are 
representative of at least three independent experiments. 
 
Fig 2 
Pharmacology of FFA4 agonist ligands in cell based assays and ex vivo lung 
tissue preparations. (a,b) Calcium concentration-response curves in Flp-In T-REx 
293 cells expressing mouse FFA1 or FFA4 stimulated with (a) TUG-891 or (b) 
TUG1197. (c) ERK1/2 concentration-response curves of CHO Flp-In cells expressing 
mouse FFA4 following 5 min stimulation with TUG-891 or TUG-1197. (d) Kinetics of 
TUG-891 and TUG-1197 mediated ERK1/2 responses at maximal concentration (1 
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μM) of each ligand. (e) Arrestin3 interaction concentration response curves of Flp-In 
T-REx 293 cells expressing recombinant mouse FFA4 stimulated with varying 
concentrations of TUG-891 or TUG-1197. (f) FFA4 phosphorylation in response to 
TUG-891 and TUG-1197 was determined in Western blots of lysates prepared from 
Flp-In T-REx 293 expressing mouse FFA4 and probed with an anti-phospho antiserum 
to pThr347/pSer350 on mouse FFA4. Parallel immunoblotting to detect GAPDH acted 
as a loading control.  (g) Internalization of eYFP-tagged mouse FFA4 expressed in 
Flp-In T-REx 293 cells following 30 minute application of TUG-891 or TUG-1197 
revealed punctate intracellular localization of FFA4 indicative of internalized receptor. 
(h-j) Elevation of intracellular calcium levels evoked by TUG-1197 in precision cut lung 
slices from (h) wild-type mice, (i) FFA4 KO(βgal) mice and (j) wild type mice in the 
presence of the Gq inhibitor FR900359. The white box indicates the area of interest 
where the fluorescence changes (changes in 340/380nm emission from the FURA2-
AM calcium indicator (FURA-2 Ratio)) are illustrated in the graph to the right of the 
images. Arrows indicate the time point at which the FFA4 agonist was added. The 
experiments shown are representative of at least three independent experiments. 
(Data in a-e are the mean ± S.E.M of at least three independent experiments).  
 
Fig 3 
Activation of FFA4 leads to airway relaxation in pre-contracted airways.  
(a,b) Representative images of the concentration-dependent relaxation responses to 
(a) TUG-891 and (b) TUG-1197 in precision cut lung slices (PCLS) pre-contracted with 
carbachol (CCh). (c,d) Quantification of the data represented in a and b. The data 
presented are the mean ± S.E.M (n=5). (e) Representative images of the effect of the 
FFA4 antagonist AH7614 on the TUG-1197-mediated relaxation response. (f) 
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Quantification of the experiment in e from at least 5 mice. (g) Representative images 
of the TUG-1197-mediated relaxation responses in PCLS from wild type and FFA4-
KO(βgal) mice. (h) Quantification of the experiment in g from at least 5 mice Data 
presented in f and h are the means ± S.E.M. of at least 5 animals where *p<0.05, 
**p<0.01 as determined by ANOVA with Bonferroni post-hoc test. 
 
Fig 4 
FFA4 agonism reduces airway resistance in healthy mice and produces 
broncho-relaxant, anti-inflammatory and prophylactic effects in ozone model of 
inflammatory lung disease. (a) Broncho-relaxant effect of TUG-1197 (0.364 mg/ml) 
on acetylcholine-induced (185 mg/ml) airway resistance in healthy wild type and 
FFA4-KO(βgal) mice. (b) Broncho-relaxant effect of TUG-1197 (0.364 mg/ml) on 
acetylcholine-induced (185 mg/ml) airway resistance in wild type and FFA4-KO(βgal) 
mice that had been exposed to ozone (3 ppm, 3 hr) 24 hours prior to the lung 
resistance experiments. (c-j) Anti-inflammatory effect of repeated administration of 
TUG-891 in a 3-week ozone exposure model. Mice were exposed with either control 
air or 3 ppm ozone for 3 hr, twice a week for 3 weeks. Before each exposure mice 
were treated with intranasal administration of either vehicle or TUG-891 (0.036 mg/ml). 
Cells in BAL fluid were obtained and enumerated for total cell counts (c) and analysed 
using flow cytometry to identify (d) alveolar macrophages, (e) monocyte derived 
macrophages (MDM) and (f) neutrophil populations. Lung tissue (left lobe) was 
isolated and RT-qPCR analysis was performed to identify changes in the expression 
of (g) KC/CXCL1 and (h) TNF-α genes. (i) Prophylactic and (j) broncho-relaxant effect 
of TUG-891 in 3-week ozone model where TUG-891 (0.036 mg/ml) was administered 
1 hr prior to each ozone exposure (i) and at the end of the ozone exposure (j), during 
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acetylcholine-induced (50 mg/ml) lung resistance measurements. Data presented are 
the mean ± S.E.M. of 4-7 animals. The data shown were analysed by Bonferroni 
multiple comparison test where *p<0.05, **p<0.01, ***p<0.001 and NS=not significant.  
 
Fig 5 
FFA4 agonism reduces increased airway resistance and lung inflammation 
induced by chronic cigarette exposure as well as airway resistance caused by 
exposure to house dust mites.  
Mice were exposed to air or cigarette smoke for 8 weeks. (a) Transpulmonary (Rrs) 
airway resistance was measured in air and smoke mice exposed to 3 mins of 
nebulized TUG-1197 (0.364 mg/ml) followed by 3 mins of nebulized methacholine (30 
mg/ml). Mice were administered daily with TUG-891 (0.364 mg/ml) prior to each 
smoke exposure and the effect of chronic TUG891 dosing on (b) macrophages and 
(c) neutrophil infiltration (in BAL fluid) was measured. Mice were sensitised with 
subcutaneous injection of either PBS or house dust mite extracts supplemented with 
Freunds complete adjuvant (CFA, 1:1 mixture 100 μg HDM) and then challenged with 
intranasal delivery of PBS or HDM (25 μg). Mice were sacrificed and total cell counts 
(d) in BAL fluid were measured. CD4+ T cells (e) and eosinophils (f) were enumerated 
by flow cytometry. Mice were administered daily with either vehicle or TUG-891 (0.182 
mg/ml) between the sensitization and final HDM challenge and the prophylactic effect 
(g) of TUG-891 on lung resistance was measured. Data represent the means ± S.D. 
of 3-9 animals where *p<0.05, **p<0.01 as determined by ANOVA with Bonferroni 
post-hoc test. 
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Fig 6. FFA4 is expressed in human bronchial epithelial cells and human smooth 
muscle cells and can be detected at both transcript and protein levels. (a) 
Transcript levels of FFA4 and 18s (as a control) were determined in bronchial epithelial 
cells (n=5 donors) and ASM cells (n=5 donors) using RT-PCR. Shown is a 
representative gel. The expected sizes of PCR products are as follow; FFA4 
251bp,18s 93 bp.  (b) Quantitative RT-PCR of bronchial epithelial cells (4 donors) and 
ASM cells (5 donors) was conducted using ACTB housekeeping gene as a control.  
Data represent mean ± SEM. (c) Western blot of human FFA4 transiently transfected 
in HEK293 cells using an antiserum selective for FFA4 developed in-house (hFFA4-
AB). (d) Immunofluorescence images of human FFA4 stably transfected in CHO-Flip-
In cells (CHO-FFA4) and control non-transfected CHO cells (CHO-NT). (e-f) Example 
fluorescent histogram of FFA4 expression (black trace) in bronchial epithelial cells and 
ASM by flow cytometry verses isotype control antibody (gray shading); fold increase 
in geometric mean fluorescence intensity (GMFI) of anti-FFA4/isotype control antibody 
(95% CI) 3.019 (2.042-3.996) [11 donors, P<0.01] and ASM cells 2.241 (1.662-2.819) 
[14 donors, P<0.001] two tailed t test against isotype control. (g,h) Representative 
photomicrograph (x40 magnification) showing bronchial epithelial cells (5 donors) 
FFA4 expression (red, left; isotype control antibody insert) and ASM cell (4 donors) 
FFA4 expression (red, right; isotype control insert) nuclei stained blue with 4’,6-
diamidino-2-phenylindino-2-phenylindole blue by immunofluorescence. (i-l) 
Representative photomicrographs of normal human bronchial biopsy sections stained 
with (i) isotype control antiserum, (j) human FFA4 selective antiserum (4 µg/ml) and 
(k) zoom of selected region of the epithelium from (l) EC = epithelial cell layer, ASM = 
airway smooth muscle. LP = Lamina propria. 
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Fig 7: Functional responses of FFA4 in isolated human lung tissues and cells. 
(a) Intracellular calcium (iCa2+) elevation in bronchial epithelial cells (6 donors) and (b) 
ASM cells (6 donors) in response to TUG-891 treatment or ionomycin (1.5µg/ml) as a 
positive control. GMFI equates to total stimulated GMFI minus matched baseline 
minus vehicle control. Data are plotted as mean ±SEM. (c) Representative gel 
photographs taken at 0 hours (basal) and 24 hours either uncontracted or pre 
contracted with carbachol (CCh 100 μM) followed by treatment of TUG-891 (50μM). 
(d) Percentage contraction of collagen gels in the presence of ASM cells (6 donors) 
either uncontracted or pre contracted with carbachol (CCh 100 μM) followed by 
treatment of TUG-891 (50 μM). Data are plotted as mean ± S.E.M. (e) Concentration-
response data for TUG-891 mediated relaxation of human airway strips pre-contracted 
with carbachol (100 μM). The data presented in e are the mean ± S.E.M of at least 
three independent experiments from healthy donors. 
 
Fig 8: FFA4 mediated airway relaxation in mouse is partly dependent on PGE2 
and the prostanoid receptor EP2. (a) PGE2 release from PCLS obtained from the 
lungs of wild-type mice and FFA4 KO(βgal) mice was detected by ELISA. (b) Effects 
of PGE2 (500 nM) treatment of carbachol (CCh) pre-contracted PCLS. (c) Effect of 
pre-treatment of PCLS with the selective EP2 receptor antagonist PF-04418948 (10 
μM) for 1 hr on TUG-891 response. (d) PGE2 release into the bronchoalveolar lavage 
fluids (BALFs) of mice exposed to normal air or chronically exposed to ozone treated 
with either vehicle (1% DMSO) or TUG891 (100 μM). Data represent the means ± S.D. 
of at least 3 animals where *p<0.05, **p<0.01, NS = not significant as determined by 
ANOVA with Bonferroni post-hoc test.  
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Materials and Methods 
Ozone exposure 
For the acute ozone exposure protocol, wild-type adult male C57BL6/N mice (8-12 wk 
old) FFA4-KO(bgal) mice (a kind gift from AstraZeneca as described previously 59  
were administered with either medical air or 3 parts per million (ppm) ozone for 3 hr in 
a sealed Perspex container (EMB104, EMMS). Ozone concentration level of 3 ppm 
was continuously monitored with an ozone probe (ATi Technologies, Ashton-U-Lyne, 
UK). 24 hr after exposure, mice were used for experiments. For sub-chronic treatment, 
mice were administered intranasally with either vehicle or FFA4 agonist (TUG-891, 
100 μM, 25 μl volume) 1 hr prior to ozone or control air treatments. Mice received 3 
parts per million (ppm) ozone produced from an ozoniser (Model 500 Sander 
Ozoniser, Germany) for 3 hours, twice a week, for a total duration of 3 weeks. Control 
animals received filtered air only for the equivalent exposure period. In some 
experiments, mice were exposed to ozone for 3 weeks and then administered TUG-
891 at the end, during the lung function measurements. 
 
House dust mite mouse model 
Adult male Balb/c mice (8-12 wk old from Envigo, Oxford, UK) were sensitized on day 
0 with subcutaneous injection of 100 μg in 100 μl volume of house dust mite extract 
(HDM, Citeq Biologics, Groningen, The Netherlands) supplemented with Freund's 
Complete Adjuvant (1:1 mixture, Sigma, Dorset, UK). Control mice were given an 
injection with equivalent volume of PBS (Life Technologies, Paisley, UK). Mice were 
then administered TUG-891 daily (500 μM, 25 μl volume) for 15 days via intranasal 
delivery under general anaesthetic. On day 15 mice were challenged with 25 μg of 
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HDM in 25 μl volume delivered intranasally under anaesthetic condition. Mice were 
used for experiments 48 hrs post challenge. 
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Supplementary Material  
 
Materials and Methods 
 
Cigarette mouse model 
6-8-week-old female wild type mice (Australian BioResources, NSW) were exposed 
to twelve 3R4F cigarettes (University of Kentucky) using a custom-designed and 
purpose-build nose-only smoke system (CH Technologies) twice per day, 5 times per 
week for 8 weeks, or room air as previously described 60-62. In some experiments, 100 
μM TUG-891 was administered daily prior to cigarette smoke exposure.  
 
Assessment of cigarette mouse model lung function 
Mice were anesthetized (50 μl/10 g i.p.) with a mixture of xylazine (2 mg/ml, Troy 
Laboratories) and ketamine (40 mg/ml, Ceva). Mice were cannulated via the trachea 
and ventilated with a tidal volume of 8 ml/kg at a rate of 450 breaths/min. FlexiVentTM 
apparatus (FX1 System; SCIREQ, Montreal, Canada) was used to assess airway 
resistance as previously described 63-65. Mice were ventilated for 5 mins before 
baseline recordings were obtained using single frequency (2.5Hz, 1.2s long; 
Snapshot-150) and broadband low frequency (1-20.5 Hz, 8s long; Quick-Prime-8) 
forced oscillation manoeuvres. Mice were then challenged with aerosolised PBS for 1 
min and Snapshot-150 and Quick-Prime-8 recorded, followed by aerosolised TUG-
1197 (0.364 mg/ml) for 3 mins (Snapshot-150 and Quick-Prime-8 recorded), and then 
aerosolised methacholine (30 mg/ml, Sigma) for 3 mins (Snapshot-150 and Quick-
Prime-8 recorded). Rrs (from Snapshot-150) and Rn (from Quick-Prime-8) were 
analysed as a percentage change from TUG-1197. 
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Bronchoalveolar lavage 
Bronchoalveolar lavage (BAL) fluids were obtained by introduction of two times 800 
µL PBS via a cannula introduced into the trachea. BAL fluids so recovered were 
centrifuged at 500g for 10 min at 4°C. Cell pellets were resuspended in PBS 
supplemented with 1% FBS and 1 mM EDTA, mixed with 4% trypan blue solution and 
counted on a Countess (Life Technologies, Pisley, UK) automated cell counter for total 
cell numbers. Remaining cells were used for flow cytometry. 
 
Immunohistochemistry of human lung biopsies 
Bronchial biopsy specimens from healthy subjects were processed and embedded  as 
described in66. 2 micron sections were then processed on the Autostainer Link 48 
platform (Dako AS480) using an automated staining protocol for the FFA4 antiserum 
(4 µg/ml)  and its rabbit polyclonal isotype control (Immunostep, Salamanca, Spain) 
using EnVision FLEX kit (Dako). Pictures were obtained using a Carl Zeiss Imager Z2 
microscope and AxioCam HRc digital camera (Carl Zeiss, Germany). 
 
Flow cytometry 
Cells obtained from BAL were resuspended in FACS buffer (PBS supplemented with 
1% FBS and 1 mM EDTA) and then stained with CD4, CD11b, CD11c, CD64, Siglec-
F, MerTK, F4/80 and Ly6G antibodies (obtained from either Biolegend, London, UK or 
Life Technology, Paisley, UK) for 30 min at 4oC. Cells were washed 3x with 1 ml FACS 
buffer and finally resuspended in 300 µL of FACS buffer for immunophenotyping. 
Staining for FFA4 expression in mouse BAL cells or human bronchial epithelial cells 
and ASM cells were performed in 0.5% triton-x100 permeabilised cells using in house 
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anti-FFA4 antisera followed by fluorescently labelled secondary antibody (Bio-Rad, 
Watford, UK). Rabbit isotype control (Immunostep, Salamanca, Spain) was used for 
definition of non-specific staining. BAL samples that were contaminated with red blood 
cells were treated with e-bioscience rbc lysis buffer (Life Technologies, Paisley, UK) 
prior to staining. Alveolar macrophages were identified as Siglec-F+, CD11c+, 
CD11bint and F4/80+ whereas gatings for neutrophils were Siglec-F-, CD11c-, 
CD11b+ as Ly6G+. Monocyte-derived macrophages were classed as CD64high, 
CD11chigh, F4/80+, MerTK+, SiglecFlow. Eosinophils were identified as being SiglecF+, 
CD11c- and CD4 positive whilst T cells were identified based on positive staining for 
CD4 glycoprotein. Flow cytometry was performed with LSRII or FACSCanto (BD 
Biosciences) instruments and data were analysed with FlowJo vX software (FlowJo 
LLC). 
 
BRET arrestin3 recruitment assay  
To assess arrestin3 recruitment to the FFA4 receptor, a bioluminescence resonance 
energy transfer (BRET) assay was used based on protocols previously described 
3,18,21. Briefly, HEK293T cells were co-transfected with arrestin3-Rluc and FLAG-
FFA4-eYFP plasmids in a 1:4 ratio using polyethyleneimine. After 24 hr incubation, 
cells were sub-cultured into poly-d-lysine-coated white 96-well microplates and 
incubated for a further 24 hr prior to the assay. Cells were then washed with Hanks' 
balanced salt solution (HBSS) and incubated in HBSS for 30 min prior to conducting 
the assay. To initiate the assay, the Rluc substrate coelenterazine-h was added to a 
final concentration of 2.5 μM and incubated for 10 min at 37 °C before the test 
compound was added. Following a further 5-min incubation, luminescence emissions 
at 535 and 475 nm were measured using a PHERAstar FS (BMG Labtech, Offenburg, 
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Germany), and the BRET signal was represented as the 535/475 ratio multiplied by 
1000 to yield the arbitrary milli-BRET units (mBRET).  
 
Ca2+ signalling in cell lines, ASM and HBEC  
Ca2+ assays were carried out on Flp-In T-REx 293 cells that inducibly express either 
FFA4 or FFA1 receptor upon treatment with doxycycline. Cells were seeded at 50 000 
cells/well in black clear-bottom 96-well plates and allowed to adhere for 3-4 hr in a 
humidified 37oC incubator at 5% CO2, 95% air.  Cells were then treated with 100 ng/ml 
doxycycline overnight to induce receptor expression. The following day, cells were 
incubated in culture medium containing the Ca2+-sensitive dye, FURA2-AM (3 µM) for 
45 min. Cells were then washed three times to remove fatty acids present in the culture 
medium and then allowed to equilibrate for 15 min in HBSS before conducting the 
assay. FURA2 fluorescent emission was measured at 510 nm following excitation at 
both 340 and 380nm using a Flexstation plate reader (Molecular Devices). Ca2+ 
responses were measured as the difference between 340:380 ratios before and after 
the addition of appropriate ligands. Alternatively, ASM and HBEC incubated in 500 μl 
of pre-warmed PBS (supplemented with 2mM Ca2+, pH7.4) containing 10 μg/ml fura-
red (Invitrogen, Paisley, UK) and 4 μg/ml fluo-3 green (Invitrogen, Paisley, UK) at 
37°C, 5% CO2 for 45 minutes in the dark. A further 500μl of pre-warmed PSS was 
added to the cells prior to centrifugation at 1300rpm for 8 minutes at 20°C. 
Supernatants were discarded and cells were resuspended in 300μl PBS in FACS tube. 
Samples were analysed using a BD FACSCanto flow cytometer. Baseline recordings 
were performed for 1 minute. Following this vehicle control, TUG-891 (30-100 µM) or 
the positive control; ionomycin (1.5 μg/ml, Sigma), was added to the cells and 
recording continued for a further 3 minutes. Ratiometric analysis of the geometric 
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mean fluorescence of fluo-3 green/fura-red was conducted as an indication of mean 
relative intracellular Ca2+ (Ca 2+i) concentration over a period of 3 minutes post-
stimulation. Data are plotted as mean± SEM. 
 
Reverse Transcriptase PCR 
Wild type female C57BL/6N or FFA4-KO(bgal) adult mice (8-12 wk old) were sacrificed 
by cervical dislocation followed by exsanguination. Lung tissue was isolated and total 
RNA was prepared from 100 mg of the tissue using an RNeasy Lipid Tissue Mini Kit 
(Qiagen) as per the manufacturer’s instructions. For human bronchial epithelial cells 
and ASM, total RNA was isolated using the peqGOLD total RNA kit (Peqlab, VWR). 
RNA concentration was verified using the nanodrop 2000 spectrophotometer 
(ThermoFisher, Waltham, USA). Complementary DNA synthesis was performed using 
SuperScript III First-Strand Synthesis SuperMix (Life Technologies) with 1 μg of total 
RNA template per reaction. Phusion DNA polymerase (New England Biolabs) was 
used in PCR reactions to amplify the gene for mouse FFA1 receptor, mouse FFA4 
receptor and α-tubulin using 2 μL of first-strand synthesis reaction products as a 
template. The following PCR program was used: 95°C 3 minutes, 95°C 30 seconds, 
60°C 30 seconds, 72°C 30 seconds (40 cycles of three last steps). PCR products were 
then analysed by electrophoresis on 2% agarose gel. The following primer pairs were 
used:  
Mouse FFA1 Forward: 5’- ACCTGCCCCCACAGTTCTCCTT-3’ 
Mouse FFA1 Reverse: 5’-AGAGTCGGGATCCCAGGCTT -3’ 
Mouse FFA4 Forward: 5’-ATGTCCCCTGAGTGTGCACA-3’ 
Mouse FFA4 Reverse: 5’-AAGAGCGTGCGGAAGAGTCG-3’ 
Mouse α-tubulin Forward: 5’-ATGCGTGAGTGCATCTCCATCCAT-3’ 
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Mouse α-tubulin Reverse: 5’-AACATTCAGGGCCCCATCAA-3’ 
Human FFA4 forward: 5’-  CCTGGAGAGATCTCGTGGGA -3’ 
Human FFA4 reverse: 5’- AGGAGGTGTTCCGAGTCTGG -3’ 
Human EP1_forward: 5’- GGTATCATGGTGGTGTCGTG -3’ 
Human EP1_reverse: 5’- GGCCTCTGGTTGTGCTTAGA -3’ 
Human EP2_forward: 5’- CCACCTCATTCTCCTGGCTA -3’ 
Human EP2_reverse: 5’- CGACAACAGAGGACTGAACG -3’ 
Human EP3_forward: 5’- CTTCGCATAACTGGGGCAAC -3’ 
Human EP3_reverse: 5’- TCTCCGTGTGTGTCTTGCAG -3’ 
Human EP4_forward: 5’- TGGTATGTGGGCTGGCTG -3’ 
Human EP4_reverse: 5’- GAGGACGGTGGCGAGAAT -3’ 
 
Quantitative RT-PCR 
Wild type C57BL/6N or FFA4-KO(bgal) adult female mice (8-10 wk old) were sacrificed 
by cervical dislocation followed by exsanguination. Lung tissue was isolated and total 
RNA was prepared from 100 mg of the tissue using an RNeasy Mini kit (Qiagen) 
following the manufacturer’s instructions. cDNA was subsequently obtained using up 
to 1 µg of RNA using the QuantiTect Reverse Transcription Kit (Qiagen). For human 
bronchial epithelial cells and ASM, total RNA was isolated using the peqGOLD total 
RNA kit (Peqlab, VWR). RNA concentration was verified using the nanodrop 2000 
spectrophotometer (ThermoFisher, Waltham, USA). 2 μL of the resulting cDNA were 
used in qPCR reactions set up with the following probes: mouse FFA4 
(Mm00725193_m1), mouse FFA1 (Mm00809442_s1), mouse GAPDH 
(Mm99999915_g1), human FFA4 (Hs00699184_m1) and human ACTB 
(Hs99999903_m1) (Life Technologies) using the 7900HT Fast Real-Time PCR 
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System (Applied Biosystems).SYBR green-based reactions were also carried out 
using the following primers: Mm_Ptges_1_SG QuantiTect Primer Assay 
(QT00118223), Mm_Ptges2_1_SG QuantiTect Primer Assay (QT00495348), 
Mm_Ptges3_1_SG QuantiTect Primer Assay (QT01759387), Mm_Il17a_1_SG 
QuantiTect Primer Assay (QT00103278), mHPRT forward  
5’-AGGCCAGACTTTGTTGGATTTGAA-3’, mHPRT reverse  
5’-CAACTTGCGCTCATCTTAGGCTTT-3’, mKC/CXCL1 forward  
5’- CGCTGCTGCTGCTGGCCACCA-3’, mKC/CXCL1 reverse  
5’-GGCTATGACTTCGGTTTGGGTGCA-3’, mCox 1 forward  
5’-GGGAATTTGTGAATGCCACC-3’, mCox 1 reverse  
5’-GGGATAAGGTTGGACCGCA-3’, mCox 2 forward  
5’-CAGACAACATAAACTGCGCCTT-3’, mCox 2 reverse  
5’-GATACACCTCTCCACCAATGACC-3, mBLT1 forward  
5’-GGCTGCAAACACTACATCTCC-3’, mBLT1 reverse  
5’-TCAGGATGCTCCACACTACAA-3’,mBLT2forward 
5’AGCCTTGGCTTTCTTCAGTTC-3’, mBLT2 reverse  
5’-CCCTCGAAGAGTCGAGTAAGG-3’ and mTNFα forward  
5’-TCTGTCTACTGAACTTCGGGGTGA-3’, mTNFα reverse  
5’- GAAGTTGACGGACCCCAAAA-3’, IL-1β forward 
5’- GCCTGCCTGAAGCTCTTGTT-3’, IL-1β reverse 
Cycling conditions were: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 
95°C for 15 s and 60°C for 1 min. Melting curve analyses were performed for all real-
time PCR runs to confirm amplification of only one product and to eliminate false 
positive results. mFFA4 and mFFA1 expression was defined relative to GAPDH and 
hFFA4 was presented relative to the reference gene ACTB and determined using the 
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equation 2-dCq, where dCq = (Cq target gene - Cq ACTB RNA) and in some cases, 
this expression was arbitrarily multiplied by the factor 106 for clearer presentation. 
Expression of CXCL1 and TNFα was defined relative to HPRT using the 
2−ΔΔCt method.  
 
Staining of lung tissues for β-galactosidase activity 
Wild type C57BL/6N or FFA4-KO(bgal) adult female mice (8-10 wk old) were sacrificed 
by cervical dislocation followed by exsanguination. Lung tissue was isolated and snap-
frozen on OCT media. Frozen lung tissues were sectioned at 5 μm thickness on a 
cryostat and stained for β-galactosidase activity using GALS kit (Sigma) according to 
the manufacturer’s instructions. 
 
Immunostaining for the FFA4 receptor in the mouse lung  
Mice were sacrificed by cervical dislocation, ensuring that the trachea remained intact. 
The chest cavity and trachea were exposed, and the trachea was cannulated. The 
lungs were gently overinflated with ice-cold 4% (wt/vol) paraformaldehyde (PFA/PBS). 
Following fixation, lungs were immediately removed and further fixed overnight in 4% 
(wt/vol) PFA/PBS at 4°C. Lungs were processed in paraffin wax, and sections from 
each lobe were taken using a microtome. Slices were either stained with haematoxylin 
and eosin or processed for antigen retrieval. Following antigen retrieval, sections were 
washed in Tris-buffered saline (TBS) plus 0.1% Triton X-100 (pH7.4) and blocked for 
2 hr at RT in TBS, 0.1% Triton X-100, 10% (vol/vol) goat serum, and 1% (wt/vol) BSA. 
Sections were incubated with an in-house rabbit anti FFA4 receptor antiserum 18 
(1:500 in blocking buffer) overnight at 4 °C. Sections were washed three times in TBS 
plus 0.1% Triton X-100 (pH7.4) and then incubated with fluorescent secondary 
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antibodies (1:1000 in blocking buffer mouse Alexa Fluor 488 from Molecular Probes, 
Inc. and 1:500 in blocking buffer anti α-smooth muscle actin-Cy3 Ab from Sigma-
Aldrich) for 2 hr at RT. Following three washes with TBS plus 0.1% Triton X-100 
(pH7.4), slices were mounted in Vectorshield hardset mounting medium containing 
DAPI. ASM cells were seeded onto 8 well chamber slides and bronchial epithelial cells 
were cultured on 25-mm glass cover slips in 6 well plates to subconfluence. Cells were 
then fixed using methanol and blocked with PBS/3% BSA. Cells were incubated with 
a rabbit polyclonal anti-FFA4 (Novus Biologicals) verses rabbit isotype control 
(Immunostep, Salamanca, Spain), followed by anti-rabbit RPE conjugated secondary 
antibody (BioRad, Watford, UK). All images were taken using either a Zeiss Axiovert 
200M microscope with a Colibri illumination system with Axiovision 4.8 software 
(Zeiss) or a Zeiss LSM 510 META NLO microscope with Zen 2009 software (Zeiss). 
Images were taken using the same magnification and microscope settings. 
 
Preparation of precision cut lung slices (PCLS)  
Wild type female C57BL/6N or FFA4-KO(bgal) adult mice (8–10 wk old) were 
sacrificed by cervical dislocation followed by exsanguination. The trachea was 
exposed and inserted with a cannula. Lungs were inflated using 1.0 ml of 2% (wt/vol) 
low gelling agarose dissolved in HBSS buffer (supplemented with 10 mM Hepes, 1 
mM MgCl2, 2 mM CaCl2 (pH 7.4)), followed by a 0.1-ml air bolus to force the agarose 
out of the airways and into the alveoli. The inflated lungs were dissected from the 
thoracic cavity and sliced using an automated vibrating microtome (VT1200S; Leica 
Biosystems) at a thickness of 200 μm. Lung slices were placed in ice-cold HBSS buffer 
supplemented with 10 mM Hepes, 1 mM MgCl2, 2 mM CaCl2 (pH 7.4) and then 
transferred to DMEM cell culture medium. Lung slices were placed in a humidified 
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incubator (37oC, 5% CO2) and the medium was changed every 30 min to 1 hr for 6 hr 
to remove any stress factors that are released during the slicing. The slices were then 
cultured overnight in DMEM and used in experiments the following day.  
 
Airway contraction and relaxation in mouse PCLS 
PCLS were placed in a 30 mm2 tissue culture dish in 3.0 mL of assay buffer (HBSS 
supplemented with 10 mM Hepes, 1 mM MgCl2, 2 mM CaCl2, pH 7.4). The airway was 
located using a microscope (Zeiss Axiovert 200M), and the slice was held in place 
using a stainless-steel ring. The camera was positioned so that a live video feed 
(AxioCAM) of the airway could be viewed. Media/DMSO were added for baseline 
measurements. A baseline image was taken, followed by the administration of the 
appropriate ligands. Images were collected every 1 min for 15-20 min per ligand 
addition. Airway luminal area was measured using the Axiovision software and data 
were plotted as a percentage of contractions of the initial (basal) airway size for the 
contractile agents. Log pEC50 and Emax values for each airway were derived from a 
concentration–response curve.  
 
Cell isolation and culture 
Pure primary ASM bundles were isolated from bronchial biopsies and from lung 
resection material. ASM cells were cultured in DMEM with glutamax-1 supplemented 
with 10% FBS, penicillin (100U/ml), streptomycin (100µg/ml), amphotericin 
(0.25µg/ml), 100µM nonessential amino acids, and 1mM sodium pyruvate (Gibco). 
ASM was cultured and characterized for a-Smooth Muscle Actin (SMA) expression 
using a mouse monoclonal anti-SMA antibody (clone 1A4, Dako) or mouse IgG2a 
isotype control (clone DAK-G05, Dako) by flow cytometry and used between passage 
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2 to 6. Basal epithelial cells obtained from nasal brushings and bronchoscopy were 
grown on collagen (Advanced Bio Matrix, San Diego, California, USA) coated 12-well 
plates in bronchial epithelial growth medium (BEGM; Lonza, Berkshire, UK) including 
supplement SingleQuot BulletKit (Lonza), 0.3% Fungizone  antimycotic (Invitrogen), 
and 1% antibiotic-antimycotic. The epithelial cells were expanded onto collagen-
coated T75cm2 flasks and replenished with fresh medium three times a week. 
 
Detection of PGE2 release by ELISA 
PCLS from the lungs of wild-type and FFA4 knock-out mice were placed in 24 well 
plates containing assay buffer and then treated with either vehicle or TUG-891 for 15 
min at 37oC. Following treatment, the supernatant was taken and analysed using 
PGE2 ELISA from Abcam (ab133021) according to the manufacturer’s instructions. 
BALF supernatants from mice undergoing in vivo experiments were also 
analysed using PGE2 ELISA to detect for the release of PGE2 into the alveolar 
spaces. The amounts of PGE2 released from the lung slices and BALF was 
determined by interpolating the sample absorbance from the standard curve. 
 
Detection of LTB4 by ELISA 
LTB4 concentrations in BALF of mice that had been chronically exposed to ozone and 
treated with TUG891 were analysed using LTB4 ELISA from R&D Systems 
(KGE006B) according to the manufacturer’s instructions. The amounts of LTB4 
released into the BALF was determined by interpolating the sample absorbance from 
the standard curve. 
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Ca2+ signalling in lung slices.   
PCLS from wild type or FFA4-KO(bgal) mice were washed twice in assay buffer 
(HBSS supplemented with 10 mM Hepes, 1 mM MgCl2, 2 mM CaCl2 (pH 7.4)) and 
incubated in the buffer containing 4 μM Fura-2:00 AM (Molecular Probes), 1 mg/mL 
BSA, and 2.5 mM probenecid for 30 min at 37 °C. After loading, the slice was placed 
in a prewarmed chamber containing assay buffer. The slice was held in place using a 
stainless-steel ring and measurements were made on a Zeiss Axiovert 200 inverted 
epifluorescence microscope with a 40× oil-immersion objective. Loaded lung slices 
were excited at 340 nm and 380 nm at a sample rate of 0.67 Hz by means of an 
excitation wheel. Sequential fluorescent image pairs were recorded at wavelengths 
>510 nm via a cooled ORCA-ER CCD camera (Hamamatsu Photonics) and processed 
with MetaFluor software (Molecular Devices). Free intracellular Ca2+ signal was 
expressed at a ratio of 340:380 or change of the ratio of fluorescence.  
 
Airway hyper-responsiveness (AHR) assessment associated with ozone 
exposure models 
Mice were anesthetized with an intraperitoneal injection of anaesthetic solution 
containing ketamine and xylazine diluted in physiological saline. Mice were 
tracheostomised and ventilated (MiniVent type 845, EMMS, Hants, UK) rate: 250 
breaths/min and tidal volume: 250 ml) and resistance/compliance measurements were 
made in a whole-body plethysmograph with a pneumotachograph connected to a 
transducer (EMMS, Hants, UK). Transpulmonary pressure was assessed via an 
oesophageal catheter (EMMS, Hants, UK). Instantaneous calculation of pulmonary 
resistance (RL) was obtained. FFA4 receptor ligands were administered with an 
AeronebH Lab Micropump Nebulizer (EMMS, Hants, UK), and RL was recorded for a 
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3-min period followed by administration of acetylcholine (128 mg/ml) (Sigma, Dorset, 
UK). RL after each ligand addition was expressed as percentage change from baseline 
RL measured following nebulized PBS (Sigma, Dorset, UK). The change in RL caused 
by acetylcholine in the presence and absence of FFA4 receptor ligands relative to 
basal RL was taken as a measure of airway responsiveness. 
 
Assessment of cigarette mouse model lung function 
Mice were anesthetized (50 μl/10 g i.p.) with a mixture of xylazine (2 mg/ml, Troy 
Laboratories) and ketamine (40 mg/ml, Ceva). Mice were cannulated via the trachea 
and ventilated with a tidal volume of 8 ml/kg at a rate of 450 breaths/min. FlexiVentTM 
apparatus (FX1 System; SCIREQ, Montreal, Canada) was used to assess airway 
resistance as previously described 63-65. Mice were ventilated for 5 mins before 
baseline recordings were obtained using single frequency (2.5Hz, 1.2s long; 
Snapshot-150) and broadband low frequency (1-20.5 Hz, 8s long; Quick-Prime-8) 
forced oscillation manoeuvres. Mice were then challenged with aerosolised PBS for 1 
min and Snapshot-150 and Quick-Prime-8 recorded, followed by aerosolised TUG-
1197 (0.364 mg/ml) for 3 mins (Snapshot-150 and Quick-Prime-8 recorded), and then 
aerosolised methacholine (30 mg/ml, Sigma) for 3 mins (Snapshot-150 and Quick-
Prime-8 recorded). Rrs (from Snapshot-150) and Rn (from Quick-Prime-8) were 
analysed as a percentage change from TUG-1197. 
 
Immunohistochemistry of human lung biopsies 
Bronchial biopsy specimens from healthy subjects were processed and embedded  as 
described in66. 2 micron sections were then processed on the Autostainer Link 48 
platform (Dako AS480) using an automated staining protocol for the FFA4 antiserum 
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(4 µg/ml)  and its rabbit polyclonal isotype control (Immunostep, Salamanca, Spain) 
using EnVision FLEX kit (Dako). Pictures were obtained using a Carl Zeiss Imager Z2 
microscope and AxioCam HRc digital camera (Carl Zeiss, Germany). 
 
Ex vivo airway contraction and relaxation in human PCLS 
Experiments were performed by Biopta Ltd (Glasgow, UK). In brief, quaternary 
branches of human bronchi from 3 healthy donors were dissected free from the 
surrounding parenchyma. Bronchi were cut into 2 mm rings and mounted in 5 ml 
myographs (Danish Myo Technology A/S) containing physiological saline solution 
(composition: 119.0 mM NaCl, 4.7 mM KCl, 1.2 mM MgS04, 24.9 mM NaHCO3, 1.2 
mM KH2PO4, 2.5 mM CaCl2, and 11.1 mM glucose), aerated with 95% O2 / 5% CO2 
gas mix, warmed and maintained at approximately 37oC. The tissue was held at a 
resting tension of 1-1.5 g, and the buffer was exchanged every 15 min for 2 h with a 
continuous digital recording of muscle force. Following this equilibration period, a pre-
determined EC80 concentration of acetylcholine (10 μM) was added to the chamber 
for 5 min or until the plateau was reached.  Concentration-response curves of TUG-
891 were constructed (10 nM–100 μM) with each concentration of the compound 
added to the tissue for 5 min or until the plateau was reached. At the end of the 
experiment, theophylline (2.2 mM) was added to induce maximal relaxation of the 
airways. 
Studies of potential off-target effects of FFA4 agonists on prostanoid receptors 
Pharmacological profiling and determination of potential off-target effects of FFA4 
agonists on prostanoid receptors were conducted (TUG-1197, study ID, FR095-
0002695, TUG-891, study ID 100025966) by Eurofins/Cerep Panlabs (Celle-
Lévescault France), a contract research organisation specialising in providing 
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pharmacological screening services. TUG-891 and TUG-1197 were screened at a 10 
μM concentration in duplicate for potential to bind to and activate or inhibit a panel of 
prostanoid receptors, EP1-4. Details and experimental conditions for these assays can 
be found online at https://www.eurofinsdiscoveryservices.com/cms/cms-
content/services/in-vitro-assays/gpcrs/.  
 
Assessment of airway smooth muscle contraction by collagen gel analysis 
Contractile properties of human airway smooth muscle (HASM) cells were assessed 
using a collagen gel contraction assay. Collagen gels were impregnated with HASM 
cells (2.5 × 105 cells) resuspended in DMEM with GlutaMAX-1 supplemented with 
penicillin (100 U·mL−1), streptomycin (100 μg·mL−1), amphotericin (0.25 μg·mL−1), 
non-essential amino acids (100 μM) (Invitrogen, Paisley, United Kingdom) and sodium 
pyruvate (1 mM). Next, 500 μL of gel mixture was added to each well of a PBS 2% 
BSA pre-coated 24-well plate and allowed to polymerize at 37°C for 90 min. After 
polymerization, 500 μL DMEM with GlutaMAX-1 (supplemented as above) was added 
to each well, and the gel was detached from the plastic surface to allow free 
contraction. Carbachol at a concentration of 100µM was added to induce contraction 
where appropriate for 1 hour prior to the addition of vehicle control, TUG-891 or AH-
7614. Images were captured over 3 hours and at 24 hours. Gel area was measured 
as a percentage of control basal well area using ImageJ software. All gel conditions 
were performed in duplicate.    
 
ERK1/2 phosphorylation assay. 
mFFA4 signaling to phospho-ERK1/2 was detected by using the HTRF phospho-
ERK1/2 (Thr202/Tyr 204) kit (Cisbio Biassays, Codolet, France). In brief, cells were 
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seeded in 96-well plates at 30,000 cells/well and grown for 48 hours before being 
serum starved overnight at 37°C. Cells were stimulated with an agonist and lysed with 
50 µl lysis buffer for 1 hour at room temperature. For concentration-response curves, 
cells were stimulated with increasing concentration of agonists for 5 minutes and for 
time-course experiments, cells were stimulated with maximal concentration of ligand 
(1 μM) for the indicated time. Lysates [16 µl] were transferred to 384-well plates and 
4 µl premixed d2/cryptate antibodies [1:1 (v/v)] were added to each lysate. The 
reaction mixtures were incubated for 2 hours at room temperature and the plate was 
read on the ClarioStar plate reader (BMG Labtech). 
 
COX-2 inhibition in chronic ozone model 
Mice (female C57BL6, age 10 - 12wk) were administered daily with either vehicle 
(1.5% DMSO), TUG891 alone (100 μM) or TUG891 in combination with the COX2 
inhibitor celecoxib (50 μM), via intranasal delivery (25 μl volume). Mice were then 
exposed to 3 ppm ozone for 3 hr, twice a week for total duration of 3 weeks. Control 
animals exposed to normal air and vehicle treatment (1.5% DMSO) were included in 
the experiments. Following treatment, mice were humanely sacrificed via an overdose 
of pentobarbitone. Once death is confirmed, mice were tracheostomised and 
bronchoalveolar lavage fluids (BALFs) were obtained. Left lung lobe from each mouse 
was dissected and snap frozen for total RNA isolation and RT-qPCR.  
 
Detection of TNFα release by ELISA 
BALF supernatants of mice from the in vivo COX-2 inhibition experiments were 
analysed using TNFα ELISA from Life Technologies (cat# # BMS6002) according to 
the manufacturer’s instructions. The amounts of TNFα released into the alveolar 
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spaces were determined by interpolating the sample absorbance from the standard 
curve. 
 
Statistical analysis  
Data were analysed by ANOVA with Bonferroni post-hoc and Student’s t-test as 
indicated.  
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Supplementary Data 
 
 
 
Fig. S1 
FFA4 activation does not cause airway contraction in murine PCLS. (a) 
Representative images of airway responses evoked by (a) the muscarinic receptor 
agonist carbachol (CCh) and serotonin (5-HT) and (b) by the FFA4 agonists TUG-891 
and TUG-1197. (c) Quantification of the data shown in a and b from at least four 
animals. The data are the mean ± S.D. 
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Fig S2 
TUG-891 mediated relaxation in pre-contracted PCLS was reduced by the FFA4 
antagonist AH7614. (a) Representative images of the effect of the FFA4 antagonist 
AH7614 on the TUG891-mediated relaxation response in PCLS pre-contracted with 
carbachol (CCh 100µM). (b) Quantification of the experiment in a from at least ten 
animals where *p<0.05 as determined by ANOVA with Bonferroni post-hoc test. 
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Fig S3 
FFA4 agonist Compound A mediates ASM relaxation in pre-contracted PCLS. 
(a) Calcium concentration response curves in CHO Flp-In cells expressing mouse 
FFA4 stimulated with TUG-891, TUG-1197 or Compound A (CmpA). (b) 
Representative images of the effect of Compound A (CmpA, 50µM), on PCLS pre-
contracted with carbachol (CCh 100µM). (c) Quantification of the experiment in b 
where significant difference between vehicle and compound A was determined by 
ANOVA with Bonferroni post-hoc test. **p<0.01. 
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Fig S4 
FFA4 agonism mediates relaxation in airways pre-contracted with serotonin. (a) 
Representative images of PCLS pre-contracted with serotonin (1 µM) followed by 
treatment with TUG-1197 (50µM). (b) Quantification of images presented in panel a. 
Data are mean ± S.D. of at least four animals where ***p<0.005 as determine by 
Student’s t test.  
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Fig S5 
FFA4 agonist TUG-891 reduces airway resistance in wild type C57BL/6 mice. 
Vehicle (Control) or TUG-891 (0.356 mg/ml) were nebulized with acetylcholine and 
administered to wild type mice and lung resistance measured. The data is expressed 
as the mean ± S.D. The data shown were analysed by unpaired t test where **p<0.01. 
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Fig S6  
FFA4 agonism did not significantly alter transcript levels of 5-Lox, BLT1, BLT2 
and IL17a but increased expression of LTB4 in chronic ozone model. FFA4 
agonism did not significantly alter transcript levels of 5-Lox, BLT1, BLT2 and IL17a 
but significantly reduced LTB4 proteins in chronic ozone model. Mice were exposed 
to either control air or 3ppm ozone for 3hrs, twice a 3 week for a total duration of 3 
weeks. Prior to each ozone exposure, mice were administered with either vehicle or 
TUG891 (0.036 mg/ml). Mice were then sacrificed and RT-qPCR analysis was 
performed in lung tissue to identify changes in the transcript levels of (a) 5-Lox, (b) 
BLT1, (c) BLT2 and (e) IL17a genes. ELISA assay was performed in BALF to identify 
changes in LTB4 protein level (d). Data represent the means ± S.D. of 6-9 animals. 
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Fig S7 
FFA4 is expressed in Gr-1+, CD11c+, and siglec-F+ immune cells. Mice were 
exposed to ozone for 3hrs, twice a 3 week for a total duration of 3 weeks. Mice were 
sacrificed and flow cytometry analysis of BALF cells was performed to detect for co-
staining of FFA4 with common markers (B220, CD3, Gr-1, CD11c and siglec-F) of 
immune cells. Data represent the means ± S.D. of 3 animals. 
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Fig S8 
FFA4 is expressed normally and fully functional in ozone-exposed mice. Mice 
were exposed to either control air or 3ppm ozone for 3hrs, twice a 3 week for a total 
duration of 3 weeks. Mice were sacrificed and RT-qPCR analysis was performed to 
identify changes in the expression of (a) FFA4 gene. PCLS were prepared from ozone-
exposed mice and stimulated with TUG891 to detect for calcium mobilisation (b-c). 
Data represent the means ± S.D. of 4-7 animals. 
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Fig S9 
Expression of FFA4 in human lung. 
a,b Two representative photomicrographs of normal human bronchial biopsy sections 
stained with the human FFA4 selective antiserum (4 µg/ml). The boxes represent the 
zoomed regions. EC = epithelial cell layer, ASM = airway smooth muscle. LP = Lamina 
propria. 
 
 
 
 
 55 
 
 
Fig S10 
PGE2 receptors are expressed in human bronchial epithelial cells and human 
airway smooth muscle cells. Transcript levels of EP1, EP2, EP3, EP4 and 18s (as 
a control) were determined in (a) bronchial epithelial cells and (b) ASM cells using RT-
PCR. Shown is a representative gel of 5 donors. The expected sizes of PCR products 
are as follows; EP1= 324bp, EP2=216bp, EP3=300bp, E4=434bp and 18s=93bp. 
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Fig S11 
FFA4 agonism upregulates the transcript levels of COX-2 in chronic ozone 
model while the transcript levels of other genes involved in the biosynthesis 
and biological actions of PGE2 remained unaltered. Mice were exposed to either 
control air or 3ppm ozone for 3hrs, twice a 3 week for a total duration of 3 weeks. Prior 
to each ozone exposure, mice were administered with either vehicle or TUG891 (0.036 
mg/ml). Mice were then sacrificed and RT-qPCR analysis was performed to identify 
changes in the transcript levels of (a) COX-1, (b) COX-2, (c) cPGES, (d) mPGES1, 
(e) mPGES2 and (f) EP2. Data represent the means ± S.D. of 6-7 animals. 
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Fig S12 
FFA4 activation mimics the anti-inflammatory effects of a COX-2 inhibitor but is 
not altered by the presence of COX-2 inhibition. (a) Total cell counts and (b) TNFα 
levels in the BALFs and (c) IL-1β expression in the lungs of mice exposed to normal 
air or chronically exposed to ozone treated with either vehicle (1.5% DMSO), TUG891 
alone (100 μM), TUG891 in combination with the COX-2 inhibitor, Celecoxib (50 μM) 
or Celecoxib alone. Data represent the means ± S.D. of at least 6 animals where 
***p<0.001, as determined by ANOVA with Bonferroni post-hoc test. 
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Receptor Ligand Response 
(% control agonist) 
EP1 TUG-891 0.9 +/- 0.0 
EP1 TUG-1197 2.1 +/- 2.1 
EP2 TUG-891 1.2 +/- 0.4 
EP2 TUG-1197 -3.8 +/- 1.0 
EP3 TUG-891 -8.4 +/- 4.2 
EP3 TUG-1197 -1.2 +/- 0.7 
EP4 TUG-891 3.0 +/- 2.3 
EP4 TUG-1197 0.0 +/- 1.9 
   
 
Table S1 
FFA4 agonists do not act as off-target agonists at prostanoid receptors. 
The effect of 10 µM of either TUG-891 or TUG-1197 to stimulate each of the EP1-4 
prostanoid receptors was compared to the maximal effect of a reference agonist. Data 
are presented as mean +/- range from two independent experiments. 
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Receptor Ligand Response 
(% inhibition of control 
agonist ) 
EP1 TUG-891 4.5 +/- 0.6 
EP1 TUG-1197 -1.2 +/- 1.8 
EP2 TUG-891 11.2 +/- 2.6 
EP2 TUG-1197 15.5 +/- 2.9 
EP3 TUG-891 -8.4 +/- 4.2 
EP3 TUG-1197 9.1 +/- 3.6 
EP4 TUG-891 6.6 +/- 4.8 
EP4 TUG-1197 7.7 +/- 3.8 
   
 
Table S2 
FFA4 agonists do not act as off-target antagonists at prostanoid receptors. 
The effect of 10 µM of either TUG-891 or TUG-1197 to inhibit response to a control 
agonist at each of the EP1-4 prostanoid receptors was assessed. Data are presented 
as mean +/- range from two independent experiments. 
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Supplementary Material  
Materials and Methods 
Fig. S1. FFA4 activation does not cause airway contraction in murine PCLS. 
Fig S2. TUG-891 mediated relaxation in pre-contracted PCLS was reduced by the 
FFA4 antagonist AH7614. 
Fig S3. FFA4 agonist Compound A mediates ASM relaxation in pre-contracted PCLS. 
Fig S4. FFA4 agonism mediates relaxation in airways pre-contracted with serotonin. 
Fig S5. FFA4 agonist TUG-891 reduces airway resistance in wild type C57BL/6 mice. 
Fig S6. FFA4 agonism did not significantly alter transcript levels of 5-Lox, BLT1, BLT2 
and IL17a but increased expression of LTB4 in chronic ozone model. 
Fig S7. FFA4 is expressed in Gr-1+, CD11c+, and siglec-F+ immune cells. 
Fig S8. FFA4 is expressed normally and fully functional in ozone-exposed mice. 
Fig S9. Expression of FFA4 in human lung. 
Fig S10. PGE2 receptors are expressed in human bronchial epithelial cells and human 
airway smooth muscle cells. 
Fig S11. FFA4 agonism upregulates the transcript levels of COX-2 in chronic ozone 
model while the transcript levels of other genes involved in the biosynthesis and 
biological actions of PGE2 remained unaltered. 
Fig S12. FFA4 activation mimics the anti-inflammatory effects of a COX-2 inhibitor but 
is not altered by the presence of COX-2 inhibition. 
Table S1. FFA4 agonists do not act as off-target agonists at prostanoid receptors. 
Table S2. FFA4 agonists do not act as off-target antagonists at prostanoid receptors. 
Supplementary Data File 1. Excel containing all the data associated with each of the 
figures. 
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